Skip to main content

Cancer Biology

School of Medicine > Cancer Biology > Faculty > Scott Weir, Pharm.D., Ph.D.

Scott Weir, Pharm.D., PhD

Director, Institute for Advancing Medical Innovation, University of Kansas
Associate Director – Translational Research, University of Kansas Cancer Center
Kelly Family Endowed IAMI Professor in Cancer Drug Discovery and Development
Pharm.D., University of Nebraska College of Pharmacy, 1980
Ph.D., University of Nebraska Medical Center, 1986

Research Interests:

Dr. Weir's research interests include clinical pharmacology, pharmacokinetics/pharmacodynamics of anti-cancer agents, lead optimization and early drug development strategies to achieve "fast into humans" translation, public-private partnerships in drug discovery and development, pediatric drug product development, biopharmaceutics characterization of drug product performance, product development-focused translational research and patient engagement in translational research.

KU Medical Center Roles:

Since joining the University of Kansas 13 years ago, Weir has established pharmaceutical industry best practices, recruited industry veterans, formed and reorganized supported cores and centers, and established strategic partnerships with industry, academia, government and disease philanthropy organizations, all focused on supporting the discovery, delivery and clinical evaluation of new drug therapies for the treatment and prevention of human disease. Weir has two roles within the University of Kansas. Weir directs the Institute for Advancing Medical Innovation (IAMI). IAMI is an academic proof of concept center that translates peer review-funded basic research into medical innovations, and using an industry approach, executes product development-focused translational research to de-risk the technologies with the intent of partnering those with promise. To date, IAMI has invested over $8.3M in 53 projects, ten of which have resulted in royalty-bearing licenses. IAMI partnered with Silvergate Pharmaceuticals and Children's Mercy Kansas City to successfully develop EpanedTM, a drug product prescribed for the treatment of cardiovascular disorders in children. This product was approved by FDA and commercially launched in 2013. IAMI's therapeutic areas of focus are cancer and rare diseases afflicting children, adolescents, and adults. IAMI partners with faculty to develop drugs, diagnostics and medical device technologies and then leads efforts to partner promising medical innovations with the private sector. In 2015, IAMI established a preferred partnership with BioNovus Innovations LLC to co-develop the most promising drug, diagnostic and medical device products created and de-risked by KU product development teams. The first co-development project supported by this unique and innovative partnership, Ciclopirox Prodrug, is currently being evaluated in a multi-center First-in-Human Phase 1 trial in patients with advanced solid tumor cancers.

In his role as associate director of translational research for the University of Kansas Cancer Center (KUCC), Weir is charged with enabling, facilitating and managing intra-programmatic and inter-programmatic translational research collaborations across the four cancer research programs. Weir also serves as a point person for establishing collaborations with other NCI Cancer Centers. Over the past eight years, KUCC and IAMI have collaborated with industry, academia, government and disease philanthropy organizations to advance 19 new cancer treatments to patients. Along with Dr. John A. Taylor III, Weir co-leads the experimental therapeutics research program within KUCC. He also co-chairs the drug discovery and development (D3SC) and investigator-initiated (TTSC) steering committees that serve as translational research catalysts for advancing promising laboratory and bedside discoveries from the bench-to-the-bedside as well as from the bedside to the bench and back again.

National Service:

From 2012-2017, Dr. Weir served on the National Center for Advancing Translational Science (NCATS) Advisory Council and Cures Acceleration Network Board. In these roles, he advised NCATS Director Christopher Austin on NIH translational research initiatives, policies, and programs. In 2013-2014, Weir co-chaired the NCATS Advisory Council Working Group, a consortium of approximately 62 clinical and translational science centers across the US, including the Kansas City regional CTSA Frontiers: University of Kansas Clinical and Translational Science Institute. Weir also served on the Best Practices for Patient Engagement team of the Clinical Trial Transformation Initiative as well as the Institute of Medicine Working Group on Mapping the Drug Discovery and Development Process. He currently serves on external or scientific advisory boards for the University of Kentucky Center for Clinical and Translational Research, Center for Drug Delivery at Washington University, Myeloproliferative Neoplasm Research Foundation and Family Health International 360, as well as serving on the board of directors for the Leo and Anne Albert Institute for Bladder Cancer Patient Care and Research.

Industry Experience:

Dr. Weir joined Marion Laboratories, Inc. in 1986 as a clinical pharmacokineticist. From 1988 through 1998, Dr. Weir assumed a series of management positions with increasing responsibility at Marion Laboratories, Inc., Marion Merrell Dow, Inc, Hoechst Marion Roussel, Inc. and Aventis Pharmaceuticals, Inc. Over this same period, Weir was directly involved in the successful registration of over 20 drug products across a wide range of therapeutic areas such as: Cardizem CD®, Cardizem Injectable®, Anzemet Tablets®, Anzemet Injectable®, Pentasa®, Carafate Tablets®, Carafate Suspension®, Priftin®, Rifater®, Ketek®, and the family of Allegra® drug products. Dr. Weir was actively involved in research and development reengineering efforts for these companies in 1992 and 1997. As well, Dr. Weir led the global integration and harmonization activities for drug metabolism and pharmacokinetics during the Hoechst Marion Roussel, Inc. merger. Following sale of the North America drug development center of Hoechst Marion Roussel, Inc. located in Kansas City, Missouri, to Quintiles, Inc. in January, 1999, Dr. Weir managed an early drug development division which included pharmacology, toxicology, drug metabolism and pharmacokinetics, bioanalytical, and clinical pharmacology services. Dr. Weir continued these responsibilities until his departure in early 2006 to join the University of Kansas Medical Center.

Selected Publications:

Weir, SJ, Patton L, Castle K, Rajewski L, Kasper H, Schimmer A:  The repositioning of the anti-fungal agent ciclopirox olamine as a novel therapeutic agent for the treatment of hematologic malignancy.   J Clin Pharmacy and Therapeutics 2011 Apr;36(2):128-143. PMID:  21366640.

Sukhai MA, Spagnuolo PA, Weir S, Kasper J, Patton L, Schimmer AD. New sources of drugs for hematologic malignancies. Blood 2011 Jun 23;117(25):6747-55. PMID:  21511957.

Song, S, Christova, T, Perusini, S, Alizadesh, S, Bao, RY, Miller, BW, Hurren, R, Jitkova, Y, Gronda, M, Isaac, M, Joseph, B, Subramanian, R, Aman, A, Chau, A, Hogge, DE, Weir, SJ, Kasper, J, Schimmer, A, Al-Awar, R, Wrana, JL, Attisano, L.  Wnt inhibitor screen reveals iron dependence on {beta}-catenin signaling in cancers.  Cancer Res  2011 Dec 15:71(24):7628-39.  Epub 2011 Oct 18.  PMID:  22009536.

Weir, SJ, DeGennaro LJ, Austin, CP.  Repurposing Approved and Abandoned Drugs for the Treatment and Prevention of Cancer through Public-Private Partnership.  Cancer Res, 2012 Mar 1;72(5):1055-8.  Epub 2012 Jan 13.  PMID:  22246671.

Kong, B, Csanaky IL, Aleksunes, LM, Patni, M, Chen, Q, Ma, X, Jaeschke, H, Weir, S, Broward, M, Klaassen, CD, Guo, GL.  Gender-specific reduction of hepatic Mrp2 expression by high-fat diet protects female mice from ANIT toxicity.  Toxicol Appl Pharmacol, 2012 Jun 1;261(2):189-195.  Epub 2012 Apr 11.  PMID:  22521610.

Hughes, M, Inglese, J, Kurtz, A, Andalibi, A, Patton, L, Austin, C, Baltezor, M, Beckloff, M, Sittampalam, S, Weingarten, M, Weir, S:  Early Drug Discovery and Development Guidelines:  For Academic Researchers, Collaborators, and Start-Up Companies.  NCBI Bookshelf, National Library of Medicine, National Institutes of Health Bookshelf ID:  NBK92015.  Epub 2012 May 1.  PMID 22553881.

Wolfe AL, Duncan KK, Parelkar NK, Weir SJ, Vielhauer GA, Boger DL. A novel, unusually efficacious duocarmycin carbamate prodrug that releases no residual byproduct. J Med Chem 2012 Jun 28;55(12):5878-86. PMC3386426.

Subramaniam D, Periyasamy G, Ponnurangam S, Chakrabarti D, Sugumar A, Padigaru M, Weir SJ, Balakrishnan A, Sharma S, Anant S. CDK-4 Inhibitor P276 Sensitizes Pancreatic Cancer Cells to Gemcitabine-Induced Apoptosis. Mol Cancer Ther 2012 Jul;11(7):1598-608. PMC3392497.

Weir SJ, Torkin R, Henney HR.  Pharmacokinetic profile of dalframpridine extended release:  Clinical relevance in patients with MS.  Curr Med Res Opin.  2013 29(12):1637-1646.  Epub 2012 Nov 16. PMID: 23157467.

Weir SJ, Gao Y, Henney HR. Population pharmacokinetics and pharmacodynamics of dalframpridine-ER in healthy volunteers and patients with MS.  Curr Med Res Opin 2013 29(12):1627-1636.  Epub 2012 Nov 16. PMID: 23157466.

Pessetto ZY, Weir SJ, Sethi G, Broward MA, Godwin AK.  Drug Repurposing for Gastrointestinal Stromal Tumor.  Mol Cancer Ther. 2013 Jul:12(7):1299-1309. Epub 2013 May 8. PMID: 23657945.

Minden MD, Hogge, DE, Weir, SJ, Kasper, J, Webster, DA, Patton, L, Jitkova, Y, Hurren, Gronda, M, Goard, CA, Rajewski, LG, Haslam, J, Heppert, KE, Schorno, K, Chang, H, Brandwein, JM, Gupta, V, Schuh, AC, Trudel, S, Yee, KW, Reed, GA, Schimmer, AD.  Oral ciclopirox olamine displays biological activity in a phase I study in patients with advanced hematologic malignancy.  Am J Hematol. 2014 89(4):363-368.  Epub 2013 Nov 25.  PMID 24273151.

Pessetto ZY, Ma Y, Hirst JJ, von Mehren M, Weir SJ, Godwin AK.  Drug Repurposing Identifies Synergistic Combination Therapy with Imatinib Mesylate for Gastrointestinal Stromal Tumors.  Mol Cancer Ther Epub 2014 Aug:13, DOI: 10.1158/1535-7163, MCT-14-0043.  PMID 25122069.

Williamson S, Johnson G, Maulhardt H, Moore K, McMeekin D, Schulz T, Reed G, Roby K, Mackay C, Smith H, Weir SJ, Wick J, Markman M, diZerga G, Baltezor M, Espinosa J, Decedue C.  A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies.  Cancer Chemother Pharmacol 2015 75:1075-1087. Epub 2015 23 April. PMID: 25898813

Last modified: Feb 28, 2019

Scott Weir, Pharm.D., Ph.D.


Scott Weir, Pharm.D., PhD
Director, Institute for Advancing Medical Innovation, University of Kansas
Associate Director – Translational Research, University of Kansas Cancer Center
Kelly Family Endowed IAMI Professor in Cancer Drug Discovery and Development

4030 Robinson; MS-1027
3901 Rainbow Blvd.
Kansas City, Kansas 66160

P: (913) 588-4798
F: (913) 588-4701